Patents by Inventor Eric L. Stangeland

Eric L. Stangeland has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Serotonin reuptake inhibitors
    Patent number: 8729119
    Abstract: In one aspect, the invention relates to compounds of formula I: where X, Y, R1, R2, R3, R4, R4, and n are as defined in the specification, or a pharmaceutically acceptable salt thereof. The compounds of formula I are serotonin reuptake inhibitors. In another aspect, the invention relates to pharmaceutical compositions comprising such compounds; methods of using such compounds; and process and intermediates for preparing such compounds.
    Type: Grant
    Filed: May 22, 2013
    Date of Patent: May 20, 2014
    Assignee: Theravance, Inc.
    Inventors: Eric L. Stangeland, Lori Jean Patterson, Daisuke Roland Saito
  • 4-[2-(2-FLUOROPHENOXY METHYL)PHENYL]PIPERIDINE COMPOUNDS
    Publication number: 20140057944
    Abstract: The invention relates to compounds of formula I: where a, R1, and R3-6 are as defined in the specification, or a pharmaceutically acceptable salt thereof. The compounds of formula I are serotonin and norepinephrine reuptake inhibitors. The invention also relates to pharmaceutical compositions comprising such compounds; methods of using such compounds; and process and intermediates for preparing such compounds.
    Type: Application
    Filed: November 4, 2013
    Publication date: February 27, 2014
    Applicant: THERAVANCE, INC.
    Inventors: Lori Jean Patterson, Eric L. Stangeland, Sheila Zipfel, Daniel D. Long
  • Serotonin reuptake inhibitors
    Patent number: 8637568
    Abstract: In one aspect, the invention relates to compounds of formula I: where Y, R1, R2, n, and Q are as defined in the specification, or a pharmaceutically acceptable salt thereof. The compounds of formula I are serotonin reuptake inhibitors. In another aspect, the invention relates to pharmaceutical compositions comprising such compounds; methods of using such compounds; and processes and intermediates for preparing such compounds.
    Type: Grant
    Filed: July 8, 2013
    Date of Patent: January 28, 2014
    Assignee: Theravance, Inc.
    Inventors: Eric L. Stangeland, Lori Jean Van Orden, Daisuke Roland Saito
  • Biphenyl derivatives
    Patent number: 8618131
    Abstract: This invention provides biphenyl derivatives of formula I: wherein R1, R2, R3, R4, R5, R6, R7, W, a, b and c are as defined in the specification, or a pharmaceutically acceptable salt or solvate or stereoisomer thereof. The biphenyl derivatives of this invention possess both ?2 adrenergic receptor agonist and muscarinic receptor antagonist activity and therefore, such biphenyl derivatives are useful for treating pulmonary disorders, such as chronic obstructive pulmonary disease and asthmas.
    Type: Grant
    Filed: July 10, 2012
    Date of Patent: December 31, 2013
    Assignee: Theravance, Inc.
    Inventors: Mathai Mammen, Sarah Dunham, Adam D. Hughes, Craig Husfeld, Eric L. Stangeland
  • DIAMIDE COMPOUNDS HAVING MUSCARINIC RECEPTOR ANTAGONIST AND BETA2 ADRENERGIC RECEPTOR AGONIST ACTIVITY
    Publication number: 20130331364
    Abstract: This invention relates to a compound of formula I: or a pharmaceutically acceptable salt thereof. Such compounds possess both muscarinic receptor antagonist and ?2 adrenergic receptor agonist activities. The invention also relates to pharmaceutical compositions comprising such compounds, processes and intermediates for preparing such compounds, and methods of using such compounds as bronchodilating agents to treat pulmonary disorders.
    Type: Application
    Filed: August 12, 2013
    Publication date: December 12, 2013
    Applicant: THERAVANCE, INC.
    Inventors: Adam D. Hughes, Yan Chen, John R. Jacobsen, Eric L. Stangeland, Rose Yen
  • 4-[2-(2-fluorophenoxymethyl)phenyl]piperidine compounds
    Patent number: 8604058
    Abstract: The invention relates to compounds of formula I: where a, R1, and R3-6 are as defined in the specification, or a pharmaceutically acceptable salt thereof. The compounds of formula I are serotonin and norepinephrine reuptake inhibitors. The invention also relates to pharmaceutical compositions comprising such compounds; methods of using such compounds; and process and intermediates for preparing such compounds.
    Type: Grant
    Filed: September 28, 2012
    Date of Patent: December 10, 2013
    Assignee: Theravance, Inc.
    Inventors: Lori Jean Patterson, Eric L. Stangeland, Sheila Zipfel, Daniel D. Long
  • 1-(2-PHENOXYMETHYLHETEROARYL) PIPERIDINE AND PIPERAZINE COMPOUNDS
    Publication number: 20130324550
    Abstract: The invention relates to compounds of formula I: where X, HAr, a, and R1 through R6 are as defined in the specification, or a pharmaceutically acceptable salt thereof. The compounds of formula I are serotonin and norepinephrine reuptake inhibitors. The invention also relates to pharmaceutical compositions comprising such compounds; methods of using such compounds; and process and intermediates for preparing such compounds.
    Type: Application
    Filed: August 9, 2013
    Publication date: December 5, 2013
    Applicant: THERAVANCE, INC.
    Inventors: Eric L. Stangeland, Lori Jean Patterson, Sheila Zipfel
  • SEROTONIN REUPTAKE INHIBITORS
    Publication number: 20130296322
    Abstract: In one aspect, the invention relates to compounds of formula I: where Y, R1, R2, n, and Q are as defined in the specification, or a pharmaceutically acceptable salt thereof. The compounds of formula I are serotonin reuptake inhibitors. In another aspect, the invention relates to pharmaceutical compositions comprising such compounds; methods of using such compounds; and processes and intermediates for preparing such compounds.
    Type: Application
    Filed: July 8, 2013
    Publication date: November 7, 2013
    Applicant: THERAVANCE, INC.
    Inventors: Eric L. Stangeland, Lori Jean Van Orden, Daisuke Roland Saito
  • Diamide compounds having muscarinic receptor antagonist and ?adrenergic receptor agonist activity
    Patent number: 8551978
    Abstract: This invention relates to a compound of formula I: or a pharmaceutically acceptable salt thereof. Such compounds possess both muscarinic receptor antagonist and ?2 adrenergic receptor agonist activities. The invention also relates to pharmaceutical compositions comprising such compounds, processes and intermediates for preparing such compounds, and methods of using such compounds as bronchodilating agents to treat pulmonary disorders.
    Type: Grant
    Filed: February 8, 2012
    Date of Patent: October 8, 2013
    Assignee: Theravance, Inc.
    Inventors: Adam D. Hughes, Yan Chen, John R. Jacobsen, Eric L. Stangeland, Rose Yen
  • SEROTONIN REUPTAKE INHIBITORS
    Publication number: 20130253013
    Abstract: In one aspect, the invention relates to compounds of formula I: where X, Y, R1, R2, R3, R4, R4, and n are as defined in the specification, or a pharmaceutically acceptable salt thereof. The compounds of formula I are serotonin reuptake inhibitors. In another aspect, the invention relates to pharmaceutical compositions comprising such compounds; methods of using such compounds; and process and intermediates for preparing such compounds.
    Type: Application
    Filed: May 22, 2013
    Publication date: September 26, 2013
    Applicant: THERAVANCE, INC.
    Inventors: Eric L. Stangeland, Lori Jean Patterson, Daisuke Roland Saito
  • 3-PHENOXYMETHYLPYRROLIDINE COMPOUNDS
    Publication number: 20130237581
    Abstract: In one aspect, the invention relates to compounds of formula I: where R1-6 are as defined in the specification, or a pharmaceutically acceptable salt thereof. The compounds of formula I are serotonin and norepinephrine reuptake inhibitors. In another aspect, the invention relates to pharmaceutical compositions comprising such compounds; methods of using such compounds; and process and intermediates for preparing such compounds.
    Type: Application
    Filed: April 25, 2013
    Publication date: September 12, 2013
    Applicant: THERAVANCE, INC.
    Inventors: Eric L. Stangeland, Jane Schmidt, Daisuke Roland Saito, Adam D. Hughes, Lori Jean Patterson
  • 1-(2-phenoxymethylheteroaryl)piperidine and piperazine compounds
    Patent number: 8530663
    Abstract: The invention relates to compounds of formula I: where X, HAr, a, and R1 through R6 are as defined in the specification, or a pharmaceutically acceptable salt thereof. The compounds of formula I are serotonin and norepinephrine reuptake inhibitors. The invention also relates to pharmaceutical compositions comprising such compounds; methods of using such compounds; and process and intermediates for preparing such compounds.
    Type: Grant
    Filed: March 21, 2011
    Date of Patent: September 10, 2013
    Assignee: Theravance, Inc.
    Inventors: Eric L. Stangeland, Lori Jean Patterson, Sheila Zipfel
  • Biphenyl compounds useful as muscarinic receptor antagonists
    Patent number: 8501776
    Abstract: The invention provides compounds of formula I: wherein a, b, c, d, n, R1, R2, R3, R6, R7, W, and A are as defined in the specification. The compounds of formula I are muscarinic receptor antagonists. The invention also provides pharmaceutical compositions containing such compounds, processes and intermediates for preparing such compounds and methods of using such compounds to treat pulmonary disorders.
    Type: Grant
    Filed: November 30, 2010
    Date of Patent: August 6, 2013
    Assignee: Theravance, Inc.
    Inventors: YuHua Ji, Craig Husfeld, Li Li, Mathai Mammen, YongQi Mu, Eric L. Stangeland
  • Serotonin reuptake inhibitors
    Patent number: 8501964
    Abstract: In one aspect, the invention relates to compounds of formula I: where Y, R1, R2, n, and Q are as defined in the specification, or a pharmaceutically acceptable salt thereof. The compounds of formula I are serotonin reuptake inhibitors. In another aspect, the invention relates to pharmaceutical compositions comprising such compounds; methods of using such compounds; and processes and intermediates for preparing such compounds.
    Type: Grant
    Filed: December 1, 2011
    Date of Patent: August 6, 2013
    Assignee: Theravance, Inc.
    Inventors: Eric L. Stangeland, Lori Jean Van Orden, Daisuke Roland Saito
  • Serotonin reuptake inhibitors
    Patent number: 8471040
    Abstract: In one aspect, the invention relates to compounds of formula I: where X, Y, R1, R2, R3, R4, R4, and n are as defined in the specification, or a pharmaceutically acceptable salt thereof. The compounds of formula I are serotonin reuptake inhibitors. In another aspect, the invention relates to pharmaceutical compositions comprising such compounds; methods of using such compounds; and process and intermediates for preparing such compounds.
    Type: Grant
    Filed: October 10, 2011
    Date of Patent: June 25, 2013
    Assignee: Theravance, Inc.
    Inventors: Eric L. Stangeland, Lori Jean Patterson, Daisuke Roland Saito
  • DIAMIDE COMPOUNDS HAVING MUSCARINIC RECEPTOR ANTAGONIST AND BETA2 ADRENERGIC RECEPTOR AGONIST ACTIVITY
    Publication number: 20130137665
    Abstract: This invention relates to a compound of formula I: or a pharmaceutically acceptable salt thereof. Such compounds possess both muscarinic receptor antagonist and ?2 adrenergic receptor agonist activities. The invention also relates to pharmaceutical compositions comprising such compounds, processes and intermediates for preparing such compounds, and methods of using such compounds as bronchodilating agents to treat pulmonary disorders.
    Type: Application
    Filed: February 8, 2012
    Publication date: May 30, 2013
    Applicant: THERAVANCE, INC.
    Inventors: Adam Hughes, Daniel Byun, Yan Chen, Melissa Fleury, John R. Jacobsen, Eric L. Stangeland, Richard D. Wilson, Rose Yen
  • 4-[2-(2-FLUOROPHENOXYMETHYL)PHENYL]PIPERIDINE COMPOUNDS
    Publication number: 20130030020
    Abstract: The invention relates to compounds of formula I: where a, R1, and R3-6 are as defined in the specification, or a pharmaceutically acceptable salt thereof. The compounds of formula I are serotonin and norepinephrine reuptake inhibitors. The invention also relates to pharmaceutical compositions comprising such compounds; methods of using such compounds; and process and intermediates for preparing such compounds.
    Type: Application
    Filed: September 28, 2012
    Publication date: January 31, 2013
    Applicant: THERAVANCE, INC.
    Inventors: Lori Jean Patterson, Eric L. Stangeland, Sheila Zipfel, Daniel D. Long
  • Biphenyl compounds useful as muscarinic receptor antagonists
    Patent number: 8329911
    Abstract: The invention provides compounds of formula I: wherein a, b, c, p, W, A, X1, R1, R2, R3, R6, R7, and R8 are as defined in the specification. The compounds of formula I are muscarinic receptor antagonists. The invention also provides pharmaceutical compositions containing such compounds, processes and intermediates for preparing such compounds and methods of using such compounds to treat pulmonary disorders.
    Type: Grant
    Filed: November 12, 2009
    Date of Patent: December 11, 2012
    Assignee: Theravance, Inc.
    Inventors: YongQi Mu, YuHua Ji, Mathai Mammen, Eric L. Stangeland
  • 4-[2-(2-fluorophenoxymethyl)phenyl]piperidine compounds
    Patent number: 8304432
    Abstract: The invention relates to compounds of formula I: where a, R1, and R3-6 are as defined in the specification, or a pharmaceutically acceptable salt thereof. The compounds of formula I are serotonin and norepinephrine reuptake inhibitors. The invention also relates to pharmaceutical compositions comprising such compounds; methods of using such compounds; and process and intermediates for preparing such compounds.
    Type: Grant
    Filed: November 13, 2009
    Date of Patent: November 6, 2012
    Assignee: Theravance, Inc.
    Inventors: Lori Jean Patterson, Eric L. Stangeland, Sheila Zipfel, Daniel D. Long
  • PROCESS FOR PREPARING 4-[2-(2-FLUOROPHENOXYMETHYL)PHENYL]PIPERIDINE COMPOUNDS
    Publication number: 20120277438
    Abstract: The invention relates to processes and intermediates for preparing compounds of formula I: where a, R1, and R3-6 are as defined in the specification, or a salt thereof. The compounds of formula I are serotonin and norepinephrine reuptake inhibitors.
    Type: Application
    Filed: July 10, 2012
    Publication date: November 1, 2012
    Applicant: THERAVANCE, INC.
    Inventors: Eric L. Stangeland, Miroslav Rapta